Merck’s KEYTRUDA® (pembrolizumab) Reduced the Risk of Disease Recurrence or Death by More than 40 Percent Compared to Placebo as Adjuvant Therapy in Resected, High-Risk Stage III Melanoma
Merck & Company, Inc. (new) (MRK)
Last merck & company, inc. (new) earnings: 4/28 06:45 am
Check Earnings Report
US:NYSE Investor Relations:
investors.merck.com/home/default.aspx
Company Research
Source: Business Wire
KEYTRUDA is First Anti-PD-1 Therapy to Show Recurrence-Free Survival (RFS) Benefit Across Stage IIIA ( 1 mm Lymph Node Metastasis), IIIB and IIIC Melanoma EORTC1325/KEYNOTE-054 Results Presented Today in Opening Plenary at AACR 2018 and Published in The New England Journal of Medicine KENILWORTH, N.J., & BRUSSELS--(BUSINESS WIRE)-- Merck (NYSE:MRK), known as MSD outside the United States and Canada, and the European Organisation for Research and Treatment of Cancer (EORTC), today announced findings from the Phase 3 EORTC1325/KEYNOTE-054 trial investigating KEYTRUDA®, Merck’s anti-PD-1 therapy, as adjuvant therapy in resected, high-risk stage III melanoma. Study results showed KEYTRUDA significantly prolonged recurrence-free survival (RFS), reducing the risk of disease recurrence or death by 43 percent compared to placebo in the overall study population (HR=0.57 [98.4% CI, 0.43-0.74]; pAme
Show less
Read more
Impact Snapshot
Event Time:
MRK
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
---|---|---|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
Last Price | ||
VWAP | ||
High:
|
Max Up |
High:
|
Low:
|
Max Down |
Low:
|
%
|
Post news range |
%
|
|
Price change |
|
|
Price Change Percentage |
|
|
S&P 500 (SPX) |
|
%
|
Volume ratio |
%
|
Volume | ||
Ticks | ||
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
MRK alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
MRK alerts
High impacting Merck & Company, Inc. (new) news events
Weekly update
A roundup of the hottest topics
MRK
News
- Merck & Co., Inc. (NYSE: MRK) had its "overweight" rating re-affirmed by analysts at Cantor Fitzgerald. They now have a $135.00 price target on the stock.MarketBeat
- Wealth Of Korea's 50 Richest On Forbes List Rises To $115 Billion [Forbes]Forbes
- Merck (MRK) Advances While Market Declines: Some Information for Investors [Yahoo! Finance]Yahoo! Finance
- Korea's 50 Richest 2024: AI Frenzy Boosts Combined Wealth To $115 Billion [Forbes]Forbes
- Merck Earnings Preview: Not Much To Fear, Plenty To Look Forward To [Seeking Alpha]Seeking Alpha
MRK
Earnings
- 2/1/24 - Beat
MRK
Sec Filings
- 4/11/24 - Form ARS
- 4/11/24 - Form DEFA14A
- 4/11/24 - Form DEF
- MRK's page on the SEC website